Related references
Note: Only part of the references are listed.The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs
Matthew N. Mills et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
Min Yan et al.
LANCET ONCOLOGY (2022)
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases
T. Jonathan Yang et al.
NEURO-ONCOLOGY (2021)
Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial
Wen-Chi Yang et al.
NEURO-ONCOLOGY (2021)
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Arlene Chan et al.
CLINICAL BREAST CANCER (2021)
Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study
Kamran A. Ahmed et al.
ADVANCES IN RADIATION ONCOLOGY (2021)
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors
Emilie Le Rhun et al.
NEURO-ONCOLOGY (2021)
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis
Markus Kuksis et al.
NEURO-ONCOLOGY (2021)
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
Priscilla K. Brastianos et al.
NATURE COMMUNICATIONS (2021)
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases
Matthew N. Mills et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A. Tawbi et al.
NEURO-ONCOLOGY (2021)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
E. Le Rhun et al.
ANNALS OF ONCOLOGY (2021)
Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review
Michelle D. Hackshaw et al.
BMC CANCER (2021)
Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
Munawar Anwar et al.
CLINICAL CANCER RESEARCH (2021)
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
Erica Michelle Stringer-Reasor et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2+breast leptomeningeal disease.
Kamran A. Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
Guy Heinrich Maria Jerusalem et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
P14.42 Neratinib for treatment of leptomeningeal metastases from HER2-positive breast cancer in extended access program: preliminary results
A Pellerino et al.
NEURO-ONCOLOGY (2021)
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
Sara A. Hurvitz et al.
ONCOLOGIST (2021)
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
M. Carausu et al.
ESMO OPEN (2021)
Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression
Norbert Galldiks et al.
NEURO-ONCOLOGY (2020)
Stereotactic Radiosurgery for Resected Brain Metastases: Single-Institutional Experience of Over 500 Cavities
Siyu Shi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Management of brain metastases in breast cancer: a review of current practices and emerging treatments
Matthew N. Mills et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Priya Kumthekar et al.
CLINICAL CANCER RESEARCH (2020)
Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
O. Metzger Filho et al.
ANNALS OF ONCOLOGY (2020)
Molecular and cellular mechanisms underlying brain metastasis of breast cancer
Mari Hosonaga et al.
CANCER AND METASTASIS REVIEWS (2020)
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
Ying Lin et al.
CANCER RESEARCH AND TREATMENT (2020)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2020)
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
F. Montemurro et al.
ANNALS OF ONCOLOGY (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Heterogeneity and vascular permeability of breast cancer brain metastases
Maria Babak et al.
CANCER LETTERS (2020)
Management of Brain and Leptomeningeal Metastases from Breast Cancer
Alessia Pellerino et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
ctDNA as a cancer biomarker: A broad overview
Luciana Santos Pessoa et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets
Damir Vareslija et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets
Damir Vareslija et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy
Nicholas B. Figura et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Leptomeningeal carcinomatosis in patients with breast cancer
Maria Alice Franzoi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases
Roshan S. Prabhu et al.
NEURO-ONCOLOGY (2019)
Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications
Adrienne Boire et al.
NEURO-ONCOLOGY (2019)
The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal
Emilie Le Rhun et al.
NEURO-ONCOLOGY (2019)
Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience
Ryan T. Hughes et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Breast leptomeningeal disease: a review of current practices and updates on management
Nicholas B. Figura et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Novel methods to diagnose leptomeningeal metastases in breast cancer
Lindsay Angus et al.
NEURO-ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid
Mark T. J. van Bussel et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review
Giuseppina Rosaria Rita Ricciardi et al.
BMC CANCER (2018)
Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology
Hamdy A. Azim et al.
CLINICAL BREAST CANCER (2018)
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
Sheheryar Kabraji et al.
CLINICAL CANCER RESEARCH (2018)
Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database
Yi-Jun Kim et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update
Naren Ramakrishna et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer
Daniel N. Cagney et al.
JAMA ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology
Gaia Griguolo et al.
ONCOLOGIST (2018)
CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY
Priya Kumthekar et al.
NEURO-ONCOLOGY (2018)
Preoperative Stereotactic Radiosurgery for Brain Metastases
David M. Routman et al.
FRONTIERS IN NEUROLOGY (2018)
Leptomeningeal metastases: a RANO proposal for response criteria
Marc Chamberlain et al.
NEURO-ONCOLOGY (2017)
Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases
Amparo Wolf et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial
Paul D. Brown et al.
LANCET ONCOLOGY (2017)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2017)
Blood-tumor barrier opening changes in brain metastases from pre to one-month post radiation therapy
Feifei Teng et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases
Nolan Priedigkeit et al.
JAMA ONCOLOGY (2017)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
E. Le Rhun et al.
ANNALS OF ONCOLOGY (2017)
Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis
Aki Morikawa et al.
CLINICAL BREAST CANCER (2017)
EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors
Bojana Milojkovic Kerklaan et al.
NEURO-ONCOLOGY (2016)
Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study
Zhenyu Pan et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery
Matthew D. Johnson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases A Randomized Clinical Trial
Paul D. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
Martin Schuler et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial
Ahmad Awada et al.
JAMA ONCOLOGY (2016)
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis
Renata Duchnowska et al.
BREAST CANCER RESEARCH (2016)
Leptomeningeal disease following stereotactic radiosurgery for brain metastases from breast cancer
Daniel M. Trifiletti et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases
Zachary A. Kohutek et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
Javier Cortes et al.
LANCET ONCOLOGY (2015)
Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U. Lin et al.
LANCET ONCOLOGY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda et al.
NATURE COMMUNICATIONS (2015)
Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines
Majid Momeny et al.
ONCOTARGET (2015)
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
I. E. Krop et al.
ANNALS OF ONCOLOGY (2015)
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma
David A. Reardon et al.
NEURO-ONCOLOGY (2015)
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
S. M. Swain et al.
ANNALS OF ONCOLOGY (2014)
Leptomeningeal disease and breast cancer: the importance of tumor subtype
Sausan Abouharb et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia
Deepa Bhojwani et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
CSF CA 15-3 in breast cancer-related leptomeningeal metastases
Emilie Le Rhun et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study
Masaaki Yamamoto et al.
LANCET ONCOLOGY (2014)
Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials
Marc Chamberlain et al.
NEURO-ONCOLOGY (2014)
Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients
Man-Hsin Hung et al.
PLOS ONE (2014)
Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
E. M. Olson et al.
ANNALS OF ONCOLOGY (2013)
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Nancy U. Lin et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis
Flora Zagouri et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Src Family Kinases as Novel Therapeutic Targets to Treat Breast Cancer Brain Metastases
Siyuan Zhang et al.
CANCER RESEARCH (2013)
Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood-brain barrier
Ankit I. Mehta et al.
CANCER TREATMENT REVIEWS (2013)
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients
Hiroji Iwata et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Risk of Leptomeningeal Disease in Patients Treated With Stereotactic Radiosurgery Targeting the Postoperative Resection Cavity for Brain Metastases
Banu Atalar et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis
S. Yust-Katz et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot et al.
LANCET ONCOLOGY (2013)
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial
Paul D. Brown et al.
NEURO-ONCOLOGY (2013)
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Epilepsy meets cancer: when, why, and what to do about it?
Michael Weller et al.
LANCET ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
Kunal S. Taskar et al.
PHARMACEUTICAL RESEARCH (2012)
Incidence and Risk Factors for Leptomeningeal Carcinomatosis in Breast Cancer Patients with Parenchymal Brain Metastases
Jong-myung Jung et al.
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY (2012)
Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer
Hideya Onishi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2011)
Leukoencephalopathy and Disseminated Necrotizing Leukoencephalopathy Following Intrathecal Methotrexate Chemotherapy and Radiation Therapy for Central Nerve System Lymphoma or Leukemia
Ji Yeon Kim et al.
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY (2011)
Survival of breast cancer patients with meningeal carcinomatosis
H. Gauthier et al.
ANNALS OF ONCOLOGY (2010)
Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman et al.
CLINICAL CANCER RESEARCH (2010)
Nomogram to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer
Olivier Graesslin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
DEGRO Practical Guidelines for Palliative Radiotherapy of Breast Cancer Patients: Brain Metastases and Leptomeningeal Carcinomatosis
Petra Feyer et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2010)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers
Elena Corsini et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2009)
COMPARATIVE RISK OF LEPTOMENINGEAL DISSEMINATION OF CANCER AFTER SURGERY OR STEREOTACTIC RADIOSURGERY FOR A SINGLE SUPRATENTORIAL SOLID TUMOR METASTASIS
Dima Suki et al.
NEUROSURGERY (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
Hans-Joachim Stemmler et al.
ANTI-CANCER DRUGS (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force
R. Soffietti et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis
AMP Omuro et al.
NEUROLOGY (2005)
The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study
W Boogerd et al.
EUROPEAN JOURNAL OF CANCER (2004)
Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis:: diagnostic and prognostic value
U Herrlinger et al.
BRITISH JOURNAL OF CANCER (2004)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
D Harari et al.
ONCOGENE (2000)
Share Paper
